First-In-Human Phase I Study Of Sy-5609, An Oral, Potent, And Selective Noncovalent Cdk7 Inhibitor, In Adult Patients With Select Advanced Solid Tumors.

Kyriakos P. Papadopoulos,Manish Sharma,Erika Paige Hamilton,Debra L. Richardson,Graeme Hodgson,Li Zhou,Angela Volkert, Hina A. Jolin,Catherine Madigan,Michael Kelly,David A. Roth

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览28

暂无评分

摘要

TPS3662Background: SY-5609 is an oral, noncovalent, highly selective and potent inhibitor of cyclin-dependent kinase 7 (CDK7), a key regulator of 2 biological processes that play critical roles in ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要